Biomatics Capital

Encodia, Inc., founded in 2015 and headquartered in San Diego, California, specializes in proteomics research and the development of innovative protein analysis technology. The company offers a platform that utilizes reverse-translation technology to convert peptide sequence information into DNA libraries, facilitating scalable and efficient protein sequencing. This capability enables researchers to analyze protein samples comprehensively, thereby advancing the field of personalized medicine. By democratizing access to detailed information on cellular processes, Encodia aims to accelerate the discovery of novel approaches to addressing challenging diseases.

Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

Omniome, Inc. is a biotechnology company based in San Diego, California, focused on developing a DNA sequencing platform that aims to deliver high accuracy in clinical sequencing. Founded in 2013, the company utilizes its proprietary Sequencing By Binding technology, which enhances nucleotide and DNA matching by harnessing the natural capabilities of polymerase. This innovative approach allows researchers to obtain accurate and rapid sequencing results at a lower cost, with the potential to significantly advance cancer diagnostics. Omniome is supported by prominent life sciences venture investors and is committed to becoming a trusted leader in the field of DNA sequencing.

AiCure is an advanced data analytics company that uses artificial intelligence to understand how patients respond to treatments. It enables intelligent decision-making and improving health outcomes. It has developed patented facial recognition and motion-sensing technology to confirm medication ingestion in real-time. AiCure's platform has the potential to revolutionize the cost-effectiveness of healthcare delivery systems by enhancing treatment and reducing risks. Their software captures and understands video, audio, and behavioral data to establish the link between patients, disease, and treatment. It was founded in 2010 and is headquartered in New York.

Blackthorn Therapeutics, based in South San Francisco, California, is a clinical-stage biopharmaceutical company focused on developing precision medicine for neurobehavioral disorders. Founded in 2013, the company utilizes a proprietary computational platform that integrates advances in computational and clinical neuroscience to better understand the relationship between brain function and behavior. By targeting dysfunctional brain circuits, Blackthorn aims to address longstanding challenges in drug discovery and development. The company’s approach involves identifying novel therapeutic targets, small molecule drug candidates, and biologically-based patient subgroups that are most likely to benefit from treatment, thereby enhancing the precision of therapeutic interventions in the central nervous system.

Thrive Earlier Detection Corp. is a healthcare company that specializes in developing advanced blood testing technologies for early cancer detection. Its flagship product, CancerSEEK, is a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma, allowing for the identification of various cancers at their nascent stages, often before symptoms manifest. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate cancer screening into standard medical practice. The company leverages real-world data and machine learning to enhance the accuracy of cancer detection, facilitate follow-up testing, and streamline the transition to oncological care. Thrive operates as a subsidiary of Exact Sciences Corporation and has received investments from notable firms including Third Rock Ventures and Section 32.

Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

Omniome, Inc. is a biotechnology company based in San Diego, California, focused on developing a DNA sequencing platform that aims to deliver high accuracy in clinical sequencing. Founded in 2013, the company utilizes its proprietary Sequencing By Binding technology, which enhances nucleotide and DNA matching by harnessing the natural capabilities of polymerase. This innovative approach allows researchers to obtain accurate and rapid sequencing results at a lower cost, with the potential to significantly advance cancer diagnostics. Omniome is supported by prominent life sciences venture investors and is committed to becoming a trusted leader in the field of DNA sequencing.

Qihan Biotech is a biomedical company based on genetic technology. Kaixin Bio ’s mission is to create a new world where patients do n’t have to wait for organ transplants. We are committed to using the world's advanced gene editing technology to produce safe and effective cells, tissues and organs that can be used for human transplantation, and to solve the serious shortage of organ transplant donors in China and the world.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic antibodies for solid tumors and hematological malignancies. Founded in 2014 and based in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to identify and develop innovative antibody therapeutics. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase I clinical trials. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, and has completed a Phase 1 dose escalation study. Additionally, CTX-8371, another bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Compass Therapeutics aims to engage the immune system effectively to advance its therapeutic offerings.

Cytrellis Biosystems, Inc. is a clinical stage medical technology company that focuses on the design and development of devices for dermatology, scar reduction, and aesthetic medicine. Founded in 2011 and headquartered in Sherborn, Massachusetts, the company aims to address age-related skin issues by offering non-surgical solutions to remove sagging skin without causing scarring. Its innovative devices provide aesthetic practitioners with advanced tools to enhance skin appearance, thereby improving patient outcomes in the field of aesthetic medicine.

Aledade, Inc. is a health technology company that supports primary care physicians in establishing and managing accountable care organizations (ACOs) across the United States. Founded in 2014 and based in Bethesda, Maryland, Aledade partners with independent primary care providers to offer a comprehensive suite of services, including data analytics, guided workflows, regulatory expertise, and payer relationships. The company also provides 360° practice support, workflow optimization, and assistance with ACO governance and contracting. By leveraging its technology platform, Aledade enables physicians to access integrated data and insights that help improve patient care, reduce costs, and maintain the autonomy of independent practices. Its tailored solutions cater to a diverse range of healthcare providers, including small practices, large practices, community health centers, and multispecialty groups.

AiCure is an advanced data analytics company that uses artificial intelligence to understand how patients respond to treatments. It enables intelligent decision-making and improving health outcomes. It has developed patented facial recognition and motion-sensing technology to confirm medication ingestion in real-time. AiCure's platform has the potential to revolutionize the cost-effectiveness of healthcare delivery systems by enhancing treatment and reducing risks. Their software captures and understands video, audio, and behavioral data to establish the link between patients, disease, and treatment. It was founded in 2010 and is headquartered in New York.

Twist Bioscience Corporation is a synthetic biology company based in South San Francisco, California, established in 2013. The company specializes in the production of synthetic DNA through its innovative DNA synthesis platform, which utilizes a proprietary semiconductor-based process on silicon chips. This approach allows for the rapid and cost-effective manufacturing of high-quality synthetic DNA, enabling applications in various fields, including healthcare, agriculture, industrial chemicals, and data storage. Twist Bioscience offers a range of products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery, and DNA for digital data storage. The company aims to empower customers in their quest for solutions that improve lives and sustainability, positioning itself as a key player in accelerating advancements in synthetic biology.

Aledade, Inc. is a health technology company that supports primary care physicians in establishing and managing accountable care organizations (ACOs) across the United States. Founded in 2014 and based in Bethesda, Maryland, Aledade partners with independent primary care providers to offer a comprehensive suite of services, including data analytics, guided workflows, regulatory expertise, and payer relationships. The company also provides 360° practice support, workflow optimization, and assistance with ACO governance and contracting. By leveraging its technology platform, Aledade enables physicians to access integrated data and insights that help improve patient care, reduce costs, and maintain the autonomy of independent practices. Its tailored solutions cater to a diverse range of healthcare providers, including small practices, large practices, community health centers, and multispecialty groups.

Blackthorn Therapeutics, based in South San Francisco, California, is a clinical-stage biopharmaceutical company focused on developing precision medicine for neurobehavioral disorders. Founded in 2013, the company utilizes a proprietary computational platform that integrates advances in computational and clinical neuroscience to better understand the relationship between brain function and behavior. By targeting dysfunctional brain circuits, Blackthorn aims to address longstanding challenges in drug discovery and development. The company’s approach involves identifying novel therapeutic targets, small molecule drug candidates, and biologically-based patient subgroups that are most likely to benefit from treatment, thereby enhancing the precision of therapeutic interventions in the central nervous system.

BlueTalon, Inc. specializes in data collaboration and unification technologies, offering solutions that enhance data-centric security for big data environments. The company's key products include the Control Your Data solution, the BlueTalon Virtual Database, and the BlueTalon Policy Engine, which collectively facilitate secure access and management of data across various platforms, including Hadoop, Spark, and SQL-based systems. These tools enable organizations to enforce precise user access controls, ensuring compliance and reducing security risks. BlueTalon's services allow users to access corporate data seamlessly across different departments and locations without the need for extensive modifications to existing databases or applications. Founded in 2013 and headquartered in Redwood City, California, BlueTalon has gained recognition for its innovative approach to data security, earning accolades such as being named a Gartner Cool Vendor in 2016. As of 2019, BlueTalon operates as a subsidiary of Microsoft Corporation, serving a wide range of clients, including Fortune 100 companies, that seek to enhance their visibility and control over sensitive data.

GRAIL, Inc. is a healthcare company dedicated to advancing technologies for early cancer detection. Founded in 2015 and based in Menlo Park, California, GRAIL has developed Galleri, a screening test aimed at asymptomatic individuals over 50, and DAC, a diagnostic aid that enhances the resolution of cancer testing for patients with clinical suspicion of cancer. The company’s signature product is a multi-cancer early detection blood test that utilizes high-intensity sequencing to measure circulating nucleic acids, allowing for the identification of various cancer types at early stages. GRAIL is also working on developing minimal residual disease tests and other post-diagnostic assessments to further enhance cancer detection and treatment.

AiCure is an advanced data analytics company that uses artificial intelligence to understand how patients respond to treatments. It enables intelligent decision-making and improving health outcomes. It has developed patented facial recognition and motion-sensing technology to confirm medication ingestion in real-time. AiCure's platform has the potential to revolutionize the cost-effectiveness of healthcare delivery systems by enhancing treatment and reducing risks. Their software captures and understands video, audio, and behavioral data to establish the link between patients, disease, and treatment. It was founded in 2010 and is headquartered in New York.